Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
REGN has been in the news recently: Fifteen analysts have provided varied ratings for Regeneron Pharmaceuticals, reflecting a range of opinions on the company's performance. Additionally, Regeneron reported strong earnings for the second quarter, amidst broader discussions led by President Trump about lowering drug prices in the pharmaceutical industry.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
